Aprepitant [Usan]
Brand names,
Aprepitant [Usan]
Analogs
Aprepitant [Usan]
Brand Names Mixture
Aprepitant [Usan]
Chemical_Formula
C23H21F7N4O3
Aprepitant [Usan]
RX_link
http://www.rxlist.com/cgi/generic3/emend.htm
Aprepitant [Usan]
fda sheet
Aprepitant [Usan]
msds (material safety sheet)
Aprepitant [Usan]
Synthesis Reference
No information avaliable
Aprepitant [Usan]
Molecular Weight
534.427 g/mol
Aprepitant [Usan]
Melting Point
No information avaliable
Aprepitant [Usan]
H2O Solubility
Practically insoluble
Aprepitant [Usan]
State
Solid
Aprepitant [Usan]
LogP
5.535
Aprepitant [Usan]
Dosage Forms
Capsule
Aprepitant [Usan]
Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
Aprepitant [Usan]
Pharmacology
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Aprepitant [Usan]
Absorption
The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
Aprepitant [Usan]
side effects and Toxicity
No information avaliable
Aprepitant [Usan]
Patient Information
Physicians should instruct their patients to read the patient package insert before starting therapy with EMEND
and to reread it each time the prescription is renewed.
Patients should be instructed to take EMEND only as prescribed. Patients should be advised to take their first
dose (125 mg) of EMEND 1 hour prior to chemotherapy treatment.
EMEND may interact with some drugs including chemotherapy; therefore, patients should be advised to report to
their doctor the use of any other prescription, non-prescription medication or herbal products.
Patients on chronic warfarin therapy should be instructed to have their clotting status closely monitored in the
2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND with each
chemotherapy cycle.
Administration of EMEND may reduce the efficacy of hormonal contraceptives. Patients should be advised to use
alternative or back-up methods of contraception during treatment with EMEND and for 1 month following the last dose
of EMEND.
Aprepitant [Usan]
Organisms Affected
Humans and other mammals